Roche Holding Ltd(RHHBY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RHHBY Roche Holding Ltd

Pre-Mkt 05-04 08:02:04 EDT Delay

盘前51.00

+0.000.00%

08:02 EDT

{"stockData":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"Roche Holding Ltd","latestPrice":51,"timestamp":1777665600000,"preClose":50.88,"halted":0,"volume":665734,"hourTrading":{"tag":"盘前","latestPrice":51,"preClose":51,"latestTime":"08:02 EDT","volume":2,"amount":102,"timestamp":1777896124529,"change":0,"changeRate":0,"amplitude":0},"delay":15,"changeRate":0.0023584905660376855,"floatShares":6371000000,"shares":6371000000,"eps":2.528533,"marketStatus":"Pre-Mkt","change":0.12,"latestTime":"05-04 08:02:04 EDT Delay","open":50.95,"high":51.3,"low":50.75,"amount":33022636.110782016,"amplitude":0.01081,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":2.528533,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1777901400000},"marketStatusCode":1,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":51,"volumeRatio":0.31336053975488576},"requestUrl":"/m/hq/s/RHHBY","defaultTab":"news","newsList":[{"id":"2630647813","title":"Roche's Vabysmo U.S. Recovery Will Be Key -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2630647813","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630647813?lang=en_us&edition=fundamental","pubTime":"2026-04-27 17:54","pubTimestamp":1777283640,"startTime":"0","endTime":"0","summary":"0953 GMT - Roche Holding flagged signs of recovery for its Vabysmo eye drug in the U.S., which will be key for the Swiss drugmaker's base business heading into the second half of the year, UBS analysts say in a research note. Vabysmo sales for the first quarter were 1% short of expectations, but Roche executives pointed to signs U.S. sales are returning to growth, UBS says. Roche's first-quarter sales were broadly as expected, though growth drivers were weaker than anticipated and legacy products exceeded forecasts, the analysts say. Going forward, new medicines like giredestrant for breast cancer, fenebrutinib for multiple sclerosis and a drug candidate for Alzheimer's disease seem key to drive Roche's top-line growth, they add. UBS raises its target price on Roche to 396 Swiss francs from 360 francs. Roche shares fall 0.3% to 321 francs. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","03165","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629190768","title":"Roche upgraded to Equal Weight from Underweight at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2629190768","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629190768?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:55","pubTimestamp":1777020916,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Sarita Kapila upgraded Roche (RHHBY) to Equal Weight from Underweight with an unchanged price target of CHF 295. The firm sa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-upgraded-to-equal-weight-from-underweight-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-upgraded-to-equal-weight-from-underweight-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2023251221.USD","LU2133065610.SGD","LU0795875086.SGD","BK4588","IE00BZ1G4Q59.USD","LU0006306889.USD","LU1668664300.SGD","LU1720051108.HKD","LU1732800096.USD","LU2271345857.HKD","LU1074936037.SGD","LU1989772923.USD","LU0314104364.USD","LU1244550221.USD","BK4534","LU1244550494.USD","LU1720051017.SGD","LU1732799900.SGD","LU1791710400.SGD","LU2111349929.HKD","LU2028103732.USD","LU2357305700.SGD","LU0106261372.USD","LU1244550577.SGD","LU0234570918.USD","LU0912757837.SGD","LU0557290698.USD","LU2089284900.SGD","BK4127","LU1363072403.SGD","LU0882574139.USD","LU0528227936.USD","LU0320765646.SGD","LU0098860793.USD","BK4585","LU0971096721.USD","03165","BK4007","LU0267386448.USD","RHHBY","IE00BKVL7J92.USD","LU0158827781.USD","LU0795875169.SGD","BK4504","LU2089283258.USD","LU2347655156.SGD","LU0106831901.USD","LU1548497426.USD","LU0158827948.USD","LU1162221912.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629680815","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Roche Holding (OtherRHHBY), Praxis Precision Medicines (PRAX) and SAB Biotherapeutics (SABS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629680815","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629680815?lang=en_us&edition=fundamental","pubTime":"2026-04-24 16:00","pubTimestamp":1777017611,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding (RHHBY), Praxis Precision Medicines ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-roche-holding-otherrhhby-praxis-precision-medicines-prax-and-sab-biotherapeutics-sabs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-roche-holding-otherrhhby-praxis-precision-medicines-prax-and-sab-biotherapeutics-sabs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009355771.USD","IE00B2B36J28.USD","XLV","LU0128526141.USD","BK4139","LU0889565916.HKD","LU0109394709.USD","BK4007","BK4137","HCSG","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4588","IE0002141913.USD","XBI","03165","LU0320765992.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","RHHBY","BK4581","SABS","LABU","LU0029874061.USD","PRAX","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629704887","title":"Roche reports Q1 group sales CHF 14.7B vs. CHF 15.4B last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2629704887","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629704887?lang=en_us&edition=fundamental","pubTime":"2026-04-23 18:18","pubTimestamp":1776939481,"startTime":"0","endTime":"0","summary":"In the first three months of 2026, Roche (RHHBY) sales were +6% at CER, -5% when reported in CHF, to CHF 14.7B due to strong demand for pharmaceuti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-reports-q1-group-sales-chf-14-7b-vs-chf-15-4b-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-reports-q1-group-sales-chf-14-7b-vs-chf-15-4b-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RHHBY","BK4007","03165"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629887011","title":"Roche expects increase in group sales in mid single digit range for FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2629887011","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629887011?lang=en_us&edition=fundamental","pubTime":"2026-04-23 18:17","pubTimestamp":1776939451,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) expects an increase in Group sales in the mid single digit range CER for 2026. Core earnings per share are targeted to develop in the...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-expects-increase-in-group-sales-in-mid-single-digit-range-for-fy26-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-expects-increase-in-group-sales-in-mid-single-digit-range-for-fy26-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["03165","RHHBY","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629859058","title":"Roche Reports In Line Sales Figures -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2629859058","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629859058?lang=en_us&edition=fundamental","pubTime":"2026-04-23 16:10","pubTimestamp":1776931800,"startTime":"0","endTime":"0","summary":"0810 GMT - Roche's first-quarter sales are largely in line with expectations, Jefferies analysts write. The Swiss pharmaceutical company will host a call later Thursday which is likely to focus on its long-term sales outlook, they write. Roche's confidence in its multiple sclerosis drug fenebrutinib will also be scrutinized, they add. Market watchers will also be interested in the commercial opportunity for its giredestrant breast cancer drug, they say. Shares are up 2.3% to 320.4 Swiss francs. ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","03165","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629888728","title":"Roche Backs Full-Year View as Quarterly Sales Rise -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2629888728","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629888728?lang=en_us&edition=fundamental","pubTime":"2026-04-23 15:31","pubTimestamp":1776929460,"startTime":"0","endTime":"0","summary":"Roche confirmed its full-year guidance after reporting a first-quarter rise in sales driven by high demand for its innovative medicines and diagnostics.The Swiss pharmaceutical giant said Thursday that sales rose 6% at constant currency to 14.72 billion Swiss francs  for the first three months of the year. Analysts were expecting group sales of 14.73 billion francs, according to a Visible Alpha consensus.Sales reported in Swiss francs fell 5% from the 15.44 billion francs it reported in the same period last year as the currency appreciated strongly, boosted by its safe-haven status amid a stormy geopolitical backdrop.Roche kept its full-year guidance unchanged. On a constant-currency basis, it sees mid single-digit percentage growth in group sales and is targeting high single-digit percentage growth in core earnings per share. Its dividend is also expected to grow, the company said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Roche Backs Full-Year View as Quarterly Sales Rise -- Update","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","03165","RHHBY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629047913","title":"Roche to Submit MS Treatment Data to Regulators Despite Deaths During Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2629047913","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629047913?lang=en_us&edition=fundamental","pubTime":"2026-04-22 22:00","pubTimestamp":1776866400,"startTime":"0","endTime":"0","summary":"Roche said it would submit trial data for its multiple sclerosis treatment fenebrutinib to regulators, despite reporting deaths of patients taking the drug during the trial.Phase-3 studies of fenebrutinib--an inhibitor for sufferers of relapsing MS--met primary endpoints of reducing relapse rates among patients in the trial, the Swiss drugmaker said Wednesday. The studies showed fenebrutinib cut relapses by half compared with a rival treatment, Roche said.\"By more than doubling the time without relapses compared to [the rival treatment], fenebrutinib may offer patients years of relapse-free living, thereby preserving both daily independence and long-term function,\" said Levi Garraway, Roche's chief medical officer. The data will now be submitted to regulatory authorities, Roche said.Nevertheless, an imbalance of deaths was observed during the trial, Roche said. Seven deaths were observed in the fenebrutinib arm, compared with one in the arm receiving the similar drug.All but two of the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roche to Submit MS Treatment Data to Regulators Despite Deaths During Trial","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106261372.USD","LU0557290698.USD","LU1363072403.SGD","LU1732799900.SGD","LU0795875086.SGD","LU2133065610.SGD","LU0225283273.USD","LU0912757837.SGD","LU0158827781.USD","LU0528227936.USD","LU0106831901.USD","LU1074936037.SGD","LU1989772840.SGD","03165","LU2023251221.USD","LU0267386448.USD","LU2357305700.SGD","LU1162221912.USD","BK4585","RHHBY","LU0234570918.USD","LU0795875169.SGD","LU1720051017.SGD","BK4581","IE00BKVL7J92.USD","LU2111349929.HKD","LU0314104364.USD","LU1548497426.USD","BK4127","LU0971096721.USD","LU1791710400.SGD","IE00BZ1G4Q59.USD","LU1244550577.SGD","LU1989772923.USD","BK4007","LU1244550494.USD","LU1668664300.SGD","LU0098860793.USD","LU0158827948.USD","LU1791710582.SGD","LU2028103732.USD","BK4516","LU0320765646.SGD","LU0006306889.USD","LU2271345857.HKD","LU2089284900.SGD","LU1720051108.HKD","BK4588","BK4504","LU1732800096.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629056902","title":"Roche's Genentech Reports Positive Phase 3 Data for Autoimmune Disorder Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2629056902","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629056902?lang=en_us&edition=fundamental","pubTime":"2026-04-22 00:23","pubTimestamp":1776788580,"startTime":"0","endTime":"0","summary":"Roche Group's Genentech said its Enspryng drug lowered the risk of relapse for patients with a type of autoimmune disorder in a Phase 3 study, meeting the study's primary endpoint.Genentech said Tuesday the treatment reduced the risk of a new relapse by 68% compared to placebo in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease .MOGAD is a rare autoimmune disease of the central nervous system that affects the optic nerves, and can also affect the brain and spinal cord. It can lead to severe symptoms such as loss of vision, pain, fatigue, numbness and cognitive dysfunction. Relapsing can lead to multiple, unpredictable attacks of worsening neurological symptoms, the company said.The data show the drug has the potential to become the first approved treatment for MOGAD, the company said. The company plans to submit the Phase 3 data to regulatory authorities globally.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Roche's Genentech Reports Positive Phase 3 Data for Autoimmune Disorder Treatment","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","BK4007","03165"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629037751","title":"This Pharma Stock Is Up 460% Over the Past Year. What Could Be Key to Future Gains. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2629037751","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629037751?lang=en_us&edition=fundamental","pubTime":"2026-04-21 22:04","pubTimestamp":1776780240,"startTime":"0","endTime":"0","summary":"Shares of Arrowhead Pharmaceuticals have soared 460% over the past year, widely outpacing the broader market. Those gains could continue if a final handful of data points fall into place.Morgan Stanley analyst Michael Ulz is eagerly awaiting the release of Phase 3 study data in the third quarter, which he expects to \"unlock a multibillion-dollar opportunity that remains underappreciated.\". The vote of confidence came as Ulz upgraded Arrowhead stock to Overweight from Equal-weight on Tuesday with a $100 price target, up from $78. Shares advanced 5% to $72.72 on Tuesday.That commentary may seem ovrly upbeat, but Morgan Stanley isn't alone in singing Arrowhead's praises. It's among the 10 firms tracked by FactSet that rate the stock at Buy or the equivalent. Just two -- Leerink Partners and Bernstein Research -- rate it at Hold.This story may be one of direct market competition, but Ulz sees tremendous potential for the broad use of plozasiran, particularly among patients at high risk of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1791710400.SGD","NVS","LU2271345857.HKD","BK4588","LU0211331839.USD","LU0314104364.USD","LU2347655156.SGD","LU2028103732.USD","LU0208291251.USD","LU0320765646.SGD","IE00BZ1G4Q59.USD","LU1791710582.SGD","LU2357305700.SGD","LU1668664300.SGD","BK4534","03165","LU0106831901.USD","BK4532","BK4585","IE00B4R5TH58.HKD","LU1732800096.USD","LU1720051108.HKD","LU1244550221.USD","LU0795875169.SGD","BK4007","BK4127","LU0557290698.USD","LU2023251221.USD","IE0009355771.USD","ARWR","LU1732799900.SGD","LU1989772840.SGD","LU0158827781.USD","LU0106261372.USD","LU0971096721.USD","IE00B2B36J28.USD","LU1244550494.USD","LU0267386448.USD","IE00BJJMRZ35.SGD","LU0225283273.USD","LU1720051017.SGD","IE00BKVL7J92.USD","LU0320765489.SGD","LU2133065610.SGD","IONS","LU1162221912.USD","LU0070302665.USD","RHHBY","LU0912757837.SGD","LU0882574139.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629087768","title":"Roche’s Genentech reports FDA approval of sBLA for Gazyva","url":"https://stock-news.laohu8.com/highlight/detail?id=2629087768","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629087768?lang=en_us&edition=fundamental","pubTime":"2026-04-21 18:10","pubTimestamp":1776766247,"startTime":"0","endTime":"0","summary":"Genentech, a member of the Roche (RHHBY) Group, announced today that the U.S. FDA has accepted the company’s supplemental Biologics License Applica...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roches-genentech-reports-fda-approval-of-sbla-for-gazyva-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roches-genentech-reports-fda-approval-of-sbla-for-gazyva-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4588","03165","RHHBY","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628217977","title":"Roche decision could hurt Sarepta in U.S., says H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2628217977","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628217977?lang=en_us&edition=fundamental","pubTime":"2026-04-17 00:20","pubTimestamp":1776356419,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Mitchell Kapoor reiterates a Sell rating on Sarepta (SRPT) with a $5 price target saying Roche’s (RHHBY) new placebo-contro...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-decision-could-hurt-sarepta-in-u-s-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-decision-could-hurt-sarepta-in-u-s-says-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","IE0009355771.USD","SRPU","IE00B2B36J28.USD","SRPT","IE00BJT1NW94.SGD","BK4139","RHHBY","IE00BJJMRZ35.SGD","BK4007","03165","IE0002141913.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627290098","title":"Roche Plans New Trial for Muscular Dystrophy Therapy to Seek EU Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2627290098","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627290098?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:10","pubTimestamp":1776341400,"startTime":"0","endTime":"0","summary":"Roche Holding said it would start a late-stage study for a gene therapy for Duchenne muscular dystrophy to seek approval in the European Union after drug regulators in the bloc turned it down last year.The Swiss drugmaker said Thursday that the new Phase 3 study for the drug, known as Elevidys, aims to generate additional data required for a regulatory resubmission with the European Medicines Agency to make it available to more patients.The EMA last year recommended the refusal of a marketing authorization for Elevidys, saying the study Roche presented to support its application failed to show the therapy had an effect on movement abilities after 12 months. Roche said at the time it would work with the EMA to explore a path forward.The company said the new study would test the efficacy and safety of Elevidys compared to placebo over 72 weeks in about 100 boys with Duchenne muscular dystrophy, a rare muscle-wasting genetic disease. The drug seeks to treat the underlying cause of the dis","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Roche Plans New Trial for Muscular Dystrophy Therapy to Seek EU Approval","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","BK4007","BK4156","03165"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133783173","title":"Earning Preview: Roche Holding Ltd this quarter’s revenue is expected to increase by 13.68%, and institutional views are neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=1133783173","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133783173?lang=en_us&edition=fundamental","pubTime":"2026-04-16 12:30","pubTimestamp":1776313814,"startTime":"0","endTime":"0","summary":"Abstract Roche Holding Ltd will report its quarterly results on April 23, 2026 before-market; investors are watching whether revenue re-accelerates and margin discipline holds following a weak prior...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: Roche Holding Ltd this quarter’s revenue is expected to increase by 13.68%, and institutional views are neutral","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626194035","title":"Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2626194035","media":"Dow Jones","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626194035?lang=en_us&edition=fundamental","pubTime":"2026-04-10 19:28","pubTimestamp":1775820480,"startTime":"0","endTime":"0","summary":"1128 GMT - Any comments from Roche Holding about its long-term prospects will be the main focal point when the group provides an update on its diagnostics business next month, UBS analysts say in a research note. Recent clinical-trial results for drug candidates giredestrant in breast cancer and fenebrutinib in multiple sclerosis, as well as for Gazyva in systemic lupus, mean investors will want to get an update from CEO Thomas Schinecker at the event scheduled for May 12, UBS says. \"We expect that Roche management will provide some indicative targets for group top-line growth, and potentially margins, relative to consensus expectations,\" the analysts say. \"We do not expect formal midterm financial guidance as the company has historically only provided 'guidance' for a single year out.\" Shares rise 0.8%. ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","03165","RHHBY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626419414","title":"Roche to Face Significant Currency Headwinds -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2626419414","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626419414?lang=en_us&edition=fundamental","pubTime":"2026-04-10 19:17","pubTimestamp":1775819820,"startTime":"0","endTime":"0","summary":"1117 GMT - Roche Holding's first-quarter update is likely to show a significant drag from currency movements, UBS analysts say in a research note. The Swiss drugmaker has flagged a 9% hit on sales from foreign exchange in the first quarter, moderating to 4% for the year as a whole if current rates are maintained, according to UBS. Among Roche's key drugs, Ocrevus for multiple sclerosis and Hemlibra for hemophilia are expected to deliver solid performances, with a more subdued result for its Vabysmo eye medicine in the U.S, the analysts say. Investors are looking to a recovery in U.S. Vabysmo growth, but UBS says it only expects a modest recovery given limited patient funding from copay assistance foundations. Shares rise 0.85%. ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","BK4007","RHHBY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625951877","title":"Roche price target lowered to $46 from $48 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2625951877","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625951877?lang=en_us&edition=fundamental","pubTime":"2026-04-07 22:35","pubTimestamp":1775572505,"startTime":"0","endTime":"0","summary":"Morgan Stanley lowered the firm’s price target on Roche (RHHBY) to $46 from $48 and keeps an Underweight rating on the shares. The firm also update...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-price-target-lowered-to-46-from-48-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-price-target-lowered-to-46-from-48-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0320765646.SGD","LU0795875086.SGD","LU0158827781.USD","BK4581","LU2357305700.SGD","03165","LU0557290698.USD","LU2089283258.USD","LU0267386448.USD","LU0106261372.USD","LU1668664300.SGD","IE00BZ1G4Q59.USD","LU1791710582.SGD","LU0225283273.USD","LU1074936037.SGD","BK4007","LU1720051108.HKD","LU2023251221.USD","LU2347655156.SGD","LU0971096721.USD","BK4516","LU1548497426.USD","LU0098860793.USD","LU0882574139.USD","LU0912757837.SGD","LU1989772923.USD","LU2028103732.USD","LU1244550494.USD","LU2133065610.SGD","LU1732800096.USD","LU0006306889.USD","BK4127","LU0106831901.USD","LU2271345857.HKD","LU0234570918.USD","LU0314104364.USD","BK4588","RHHBY","LU1363072403.SGD","BK4585","LU2089284900.SGD","LU1732799900.SGD","LU2111349929.HKD","LU1244550221.USD","LU1989772840.SGD","LU1162221912.USD","LU1720051017.SGD","LU0795875169.SGD","LU1791710400.SGD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625607396","title":"AbbVie, Genentech to sell popular commercial drugs on TrumpRx, CBS says","url":"https://stock-news.laohu8.com/highlight/detail?id=2625607396","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625607396?lang=en_us&edition=fundamental","pubTime":"2026-04-07 06:20","pubTimestamp":1775514054,"startTime":"0","endTime":"0","summary":"AbbVie (ABBV) and Roche’s (RHHBY) Genentech will be the two latest drug makers to officially begin selling popular commercial medications on the Wh...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abbvie-genentech-to-sell-popular-commercial-drugs-on-trumprx-cbs-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abbvie-genentech-to-sell-popular-commercial-drugs-on-trumprx-cbs-says-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1551013342.USD","IE000SO60NU8.SGD","LU0868494617.USD","LU2237443622.USD","LU1496350171.SGD","LU0098860793.USD","LU0198837287.USD","LU0708994859.HKD","SG9999015952.SGD","LU0057025933.USD","LU2237443978.SGD","IE0002141913.USD","LU1023059063.AUD","LU1718418525.SGD","LU0417517546.SGD","BK4534","LU1037948897.HKD","LU0310800379.SGD","LU0823416689.USD","LU0738911758.USD","SG9999003800.SGD","SG9999011175.SGD","LU0211328371.USD","LU2089984988.USD","SG9999001440.SGD","LU2129689605.HKD","LU0861579265.USD","LU0985320562.USD","03165","LU2468319806.SGD","LU0511384066.AUD","LU0122379950.USD","LU0942090050.USD","LU0203347892.USD","LU0820561909.HKD","RHHBY","SG9999015978.USD","LU0289739343.SGD","IE0000B7K699.USD","LU1585245621.USD","LU0661504455.SGD","BK4566","LU0256863811.USD","LU0689626769.HKD","LU2237443895.HKD","LU1074936037.SGD","IE00B19Z3581.USD","LU1430594728.SGD","ABBV","LU0912757837.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625749456","title":"Analysts Offer Insights on Healthcare Companies: Roche Holding (OtherRHHBY), Nutriband (NTRB) and REPRO-MED Systems (KRMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625749456","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625749456?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:20","pubTimestamp":1775481609,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Roche Holding (RHHBY), Nutriband (NTRB) and REPRO-ME...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-roche-holding-otherrhhby-nutriband-ntrb-and-repro-med-systems-krmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-roche-holding-otherrhhby-nutriband-ntrb-and-repro-med-systems-krmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4585","RHHBY","LU0029874061.USD","LU0128526141.USD","03165","XBI","BK4082","MED","BK4137","BK4007","BK4183","BK4588","BK4532","XLV","LABU","KRMD","HCSG","NTRB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625748596","title":"Roche upgraded to Buy from Hold at Argus","url":"https://stock-news.laohu8.com/highlight/detail?id=2625748596","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625748596?lang=en_us&edition=fundamental","pubTime":"2026-04-06 20:50","pubTimestamp":1775479852,"startTime":"0","endTime":"0","summary":"Argus upgraded Roche (RHHBY) to Buy from Hold with a $55 price target The firm is positive on the company’s strong line-up of blockbuster products,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-upgraded-to-buy-from-hold-at-argus-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-upgraded-to-buy-from-hold-at-argus-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["03165","BK4007","RHHBY"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.roche.com","stockEarnings":[{"period":"1week","weight":-0.0006},{"period":"1month","weight":0.0654},{"period":"3month","weight":0.0843},{"period":"6month","weight":0.0925},{"period":"1year","weight":0.22},{"period":"ytd","weight":0.1631}],"description":"Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at  transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.","exchange":"OTCQX","name":"Roche Holding Ltd","nameEN":"Roche Holding Ltd","securityTypeName":"DR","adrRate":"1:0"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roche Holding Ltd(RHHBY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roche Holding Ltd(RHHBY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roche Holding Ltd,RHHBY,Roche Holding Ltd股票,Roche Holding Ltd股票老虎,Roche Holding Ltd股票老虎国际,Roche Holding Ltd行情,Roche Holding Ltd股票行情,Roche Holding Ltd股价,Roche Holding Ltd股市,Roche Holding Ltd股票价格,Roche Holding Ltd股票交易,Roche Holding Ltd股票购买,Roche Holding Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roche Holding Ltd(RHHBY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roche Holding Ltd(RHHBY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction